Business Context and Reporting Period
This Form 8-K Current Report was filed by Brucker Corporation on January 10, 2014. The report discloses a corporate governance event: the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Gilles Martin to the Board of Directors, effective January 13, 2014, to fill a vacancy. Dr. Martin will serve as a Class III director with a term expiring at the 2015 Annual Meeting of Stockholders.
Management Commentary and Risks
- Director Background: Dr. Martin is the Chairman and CEO of Eurofins Scientific Group, an international life sciences company. He holds a Ph.D. in Statistics and Applied Mathematics.
- Compensation: His compensation will be consistent with other non-employee directors as described in the 2013 Annual Meeting proxy statement.
- Related Party Transactions: The filing states there are no other arrangements or understandings regarding his election, and he is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Dr. Martin's board service (January 13, 2014).
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Confirm Dr. Martin's compensation structure by referencing the 2013 Annual Meeting proxy statement.
- Note that this filing contains no financial results; refer to the most recent 10-K or 10-Q for financial metrics.